<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Oncology &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/oncology/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>A second-look at node-negative or DCIS breast pathology worth it</title>
		<link>http://www.thedoctorschannel.com/view/a-second-look-at-node-negative-or-dcis-breast-pathology-worth-it/</link>
		<pubDate>Thu, 10 May 2012 21:09:22 +0000</pubDate> 
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pathology & Lab Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[Women’s Health]]></category>
		<category><![CDATA[breast cancer]]></category>
		<category><![CDATA[dcis]]></category>
		<category><![CDATA[pathology]]></category>
		<category><![CDATA[second opinion]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31610</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Getting a second opinion of surgical breast pathology often leads to changes that impact treatment in women with node-negative breast cancer or ductal carcinoma in situ (DCIS), clinicians with the British Columbia Cancer Agency (BCCA) in Vancouver have found. In an email to Reuters Health, first author Dr. Hagan F. -]]></description>
		
			<media:content duration="1:25" medium="video">
		<media:title><![CDATA[A second-look at node-negative or DCIS breast pathology worth it]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Getting a second opinion of surgical breast pathology often leads to changes that impact treatment in women with node-negative breast cancer or ductal carcinoma in situ (DCIS), clinicians with the British Columbia Cancer Agency (BCCA) in Vancouver have found. In an email to Reuters Health, first author Dr. Hagan F. -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/a-second-look-at-node-negative-or-dcis-breast-pathology-worth-it/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120510epid003.jpg"/>
	<media:keywords><![CDATA[breast cancer,dcis,pathology,second opinion]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Neoadjuvant chemotherapy improves survival in urothelial cancer</title>
		<link>http://www.thedoctorschannel.com/view/neoadjuvant-chemotherapy-improves-survival-in-urothelial-cancer-2/</link>
		<pubDate>Wed, 09 May 2012 21:37:37 +0000</pubDate> 
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[Urology]]></category>
		<category><![CDATA[SCUC]]></category>
		<category><![CDATA[Small-cell urothelial cancer]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31309</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Chemotherapy given before surgery in patients with small-cell urothelial cancer (SCUC) downstages tumors and results in significantly improved survival, a team from the University of Texas M.D Anderson Cancer Center reports. “Although limited by a small sample size and retrospective analysis, in the context of a rare disease, this experience -]]></description>
		
			<media:content duration="1:22" medium="video">
		<media:title><![CDATA[Neoadjuvant chemotherapy improves survival in urothelial cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Chemotherapy given before surgery in patients with small-cell urothelial cancer (SCUC) downstages tumors and results in significantly improved survival, a team from the University of Texas M.D Anderson Cancer Center reports. “Although limited by a small sample size and retrospective analysis, in the context of a rare disease, this experience -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/neoadjuvant-chemotherapy-improves-survival-in-urothelial-cancer-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120509clin002.jpg"/>
	<media:keywords><![CDATA[SCUC,Small-cell urothelial cancer]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Metformin may prevent liver cancer in type 2 diabetes</title>
		<link>http://www.thedoctorschannel.com/view/metformin-may-prevent-liver-cancer-in-type-2-diabetes/</link>
		<pubDate>Wed, 09 May 2012 21:35:04 +0000</pubDate> 
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[colorectal]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[liver]]></category>
		<category><![CDATA[metformin]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31303</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Metformin appears to lower the risk of developing liver cancer in patients with type 2 diabetes, according to the results of a meta-analysis reported in the July issue of the Journal of Clinical Endocrinology and Metabolism. However, “Further investigation, including mechanistic studies, well-designed cohort studies, and possibly controlled trials, is -]]></description>
		
			<media:content duration="1:22" medium="video">
		<media:title><![CDATA[Metformin may prevent liver cancer in type 2 diabetes]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Metformin appears to lower the risk of developing liver cancer in patients with type 2 diabetes, according to the results of a meta-analysis reported in the July issue of the Journal of Clinical Endocrinology and Metabolism. However, “Further investigation, including mechanistic studies, well-designed cohort studies, and possibly controlled trials, is -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/metformin-may-prevent-liver-cancer-in-type-2-diabetes/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120509clin006.jpg"/>
	<media:keywords><![CDATA[cancer,colorectal,diabetes,liver,metformin]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Single-agent maintenance improves survival in NSCLC</title>
		<link>http://www.thedoctorschannel.com/view/single-agent-maintenance-improves-survival-in-nsclc-2/</link>
		<pubDate>Tue, 08 May 2012 22:17:42 +0000</pubDate> 
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Maintenance therapy]]></category>
		<category><![CDATA[NSCLC]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31262</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – After a standard course of combination chemotherapy for advanced non-small-cell lung cancer, maintenance therapy with a single agent improves overall survival and progression-free survival, results of a meta-analysis show. However, “statistical significance was only noted with ‘switch’ maintenance,” i.e., with an agent not in the initial combination regimen, the authors -]]></description>
		
			<media:content duration="1:36" medium="video">
		<media:title><![CDATA[Single-agent maintenance improves survival in NSCLC]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – After a standard course of combination chemotherapy for advanced non-small-cell lung cancer, maintenance therapy with a single agent improves overall survival and progression-free survival, results of a meta-analysis show. However, “statistical significance was only noted with ‘switch’ maintenance,” i.e., with an agent not in the initial combination regimen, the authors -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/single-agent-maintenance-improves-survival-in-nsclc-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120508clin0021.jpg"/>
	<media:keywords><![CDATA[Maintenance therapy,NSCLC]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Albumin-bound paclitaxel improves treatment of advanced lung cancer</title>
		<link>http://www.thedoctorschannel.com/view/albumin-bound-paclitaxel-improves-treatment-of-advanced-lung-cancer/</link>
		<pubDate>Fri, 04 May 2012 21:24:47 +0000</pubDate> 
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[albumin]]></category>
		<category><![CDATA[nab-paclitaxel]]></category>
		<category><![CDATA[non-small-cell lung cancer]]></category>
		<category><![CDATA[NSCLC]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30981</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Patients with advanced non-small-cell lung cancer have higher response rates to a regimen that includes an albumin-bound formulation of paclitaxel (nab-paclitaxel) than solvent-based paclitaxel, an international team reports in the Journal of Clinical Oncology online April 30. In particular, patients with squamous cell histology responded “remarkably well” to the nab-paclitaxel -]]></description>
		
			<media:content duration="1:28" medium="video">
		<media:title><![CDATA[Albumin-bound paclitaxel improves treatment of advanced lung cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Patients with advanced non-small-cell lung cancer have higher response rates to a regimen that includes an albumin-bound formulation of paclitaxel (nab-paclitaxel) than solvent-based paclitaxel, an international team reports in the Journal of Clinical Oncology online April 30. In particular, patients with squamous cell histology responded “remarkably well” to the nab-paclitaxel -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/albumin-bound-paclitaxel-improves-treatment-of-advanced-lung-cancer/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120504drgd007.jpg"/>
	<media:keywords><![CDATA[albumin,nab-paclitaxel,non-small-cell lung cancer,NSCLC]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Cardiac risks high in childhood cancer survivors</title>
		<link>http://www.thedoctorschannel.com/view/cardiac-risks-high-in-childhood-cancer-survivors-2/</link>
		<pubDate>Tue, 01 May 2012 23:15:46 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[anthracyclines]]></category>
		<category><![CDATA[cardiac]]></category>
		<category><![CDATA[childhood cancer]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30463</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Depending on the treatment they received, survivors of childhood cancer may require long-term follow-up because of an elevated risk of symptomatic cardiac events, Dutch researchers report in an April 2nd online paper in the Journal of Clinical Oncology. As Dr. Helena J. van der Pal told Reuters Health by email, -]]></description>
		
			<media:content duration="1:37" medium="video">
		<media:title><![CDATA[Cardiac risks high in childhood cancer survivors]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Depending on the treatment they received, survivors of childhood cancer may require long-term follow-up because of an elevated risk of symptomatic cardiac events, Dutch researchers report in an April 2nd online paper in the Journal of Clinical Oncology. As Dr. Helena J. van der Pal told Reuters Health by email, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/cardiac-risks-high-in-childhood-cancer-survivors-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120501epid0011.jpg"/>
	<media:keywords><![CDATA[anthracyclines,cardiac,childhood cancer]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Low-dose aspirin may prevent nonvascular deaths</title>
		<link>http://www.thedoctorschannel.com/view/low-dose-aspirin-may-prevent-nonvascular-deaths-2/</link>
		<pubDate>Mon, 30 Apr 2012 22:50:46 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[aspirin]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[nonvascular mortality]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30383</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Daily low-dose aspirin reduces not only cardiovascular mortality but also nonvascular mortality – and cancer mortality in particular &#8212; after relatively short duration of treatment, according to the results of a meta-analysis published in the American Journal of Medicine online April 18. “The impact of widespread aspirin use on cancer -]]></description>
		
			<media:content duration="1:27" medium="video">
		<media:title><![CDATA[Low-dose aspirin may prevent nonvascular deaths]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Daily low-dose aspirin reduces not only cardiovascular mortality but also nonvascular mortality – and cancer mortality in particular &#8212; after relatively short duration of treatment, according to the results of a meta-analysis published in the American Journal of Medicine online April 18. “The impact of widespread aspirin use on cancer -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/low-dose-aspirin-may-prevent-nonvascular-deaths-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120430clin002.jpg"/>
	<media:keywords><![CDATA[aspirin,cancer,nonvascular mortality]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Adjuvant therapy beneficial in high-risk biliary tract tumors: meta-analysis</title>
		<link>http://www.thedoctorschannel.com/view/adjuvant-therapy-beneficial-in-high-risk-biliary-tract-tumors-meta-analysis/</link>
		<pubDate>Fri, 27 Apr 2012 19:07:48 +0000</pubDate> 
				<category><![CDATA[Gastroenterology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[adjuvant therapy]]></category>
		<category><![CDATA[Biliary tumor]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30276</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A systematic review and meta-analysis provides “reasonable” support for the current practice of giving adjuvant therapy to patients with resected biliary tract cancer with high-risk features, researchers conclude. “We found from our review that adjuvant therapy, mainly chemotherapy, appears to offer a survival advantage to those patients with biliary cancer -]]></description>
		
			<media:content duration="1:31" medium="video">
		<media:title><![CDATA[Adjuvant therapy beneficial in high-risk biliary tract tumors: meta-analysis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A systematic review and meta-analysis provides “reasonable” support for the current practice of giving adjuvant therapy to patients with resected biliary tract cancer with high-risk features, researchers conclude. “We found from our review that adjuvant therapy, mainly chemotherapy, appears to offer a survival advantage to those patients with biliary cancer -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/adjuvant-therapy-beneficial-in-high-risk-biliary-tract-tumors-meta-analysis/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120427clin0021.jpg"/>
	<media:keywords><![CDATA[adjuvant therapy,Biliary tumor]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Add-on bevacizumab slows progression of recurrent ovarian cancer</title>
		<link>http://www.thedoctorschannel.com/view/add-on-bevacizumab-slows-progression-of-recurrent-ovarian-cancer-2/</link>
		<pubDate>Wed, 25 Apr 2012 21:43:45 +0000</pubDate> 
				<category><![CDATA[Ob/Gyn]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Women’s Health]]></category>
		<category><![CDATA[Bevacizumab]]></category>
		<category><![CDATA[carboplatin ovarian cancer]]></category>
		<category><![CDATA[gemcitabine]]></category>
		<category><![CDATA[OCEANS trial]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30200</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Progression-free survival (PFS) is significantly longer in women with recurrent ovarian cancer when bevacizumab is added to chemotherapy, a multicenter team reports in the Journal of Clinical Oncology online April 23. “As ovarian cancer becomes a chronic illness, treatments that prolong PFS, and therefore time without cytotoxic chemotherapy, become increasingly -]]></description>
		
			<media:content duration="1:18" medium="video">
		<media:title><![CDATA[Add-on bevacizumab slows progression of recurrent ovarian cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Progression-free survival (PFS) is significantly longer in women with recurrent ovarian cancer when bevacizumab is added to chemotherapy, a multicenter team reports in the Journal of Clinical Oncology online April 23. “As ovarian cancer becomes a chronic illness, treatments that prolong PFS, and therefore time without cytotoxic chemotherapy, become increasingly -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/add-on-bevacizumab-slows-progression-of-recurrent-ovarian-cancer-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120425drgd005.jpg"/>
	<media:keywords><![CDATA[Bevacizumab,carboplatin ovarian cancer,gemcitabine,OCEANS trial]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Naproxen lessens pegfilgrastim-induced bone pain</title>
		<link>http://www.thedoctorschannel.com/view/naproxen-lessens-pegfilgrastim-induced-bone-pain/</link>
		<pubDate>Mon, 23 Apr 2012 22:18:27 +0000</pubDate> 
				<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[naproxen]]></category>
		<category><![CDATA[pegfilgrastim]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=28428</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Cancer patients given pegfilgrastim experience less bone pain if they take naproxen 500 mg twice daily for about a week, according to the results of a randomized placebo-controlled trial reported in the Journal of Clinical Oncology online April 16. Naproxen reduced the percentage of patients who experienced any pain, the -]]></description>
		
			<media:content duration="1:31" medium="video">
		<media:title><![CDATA[Naproxen lessens pegfilgrastim-induced bone pain]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Cancer patients given pegfilgrastim experience less bone pain if they take naproxen 500 mg twice daily for about a week, according to the results of a randomized placebo-controlled trial reported in the Journal of Clinical Oncology online April 16. Naproxen reduced the percentage of patients who experienced any pain, the -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/naproxen-lessens-pegfilgrastim-induced-bone-pain/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120423clin002.jpg"/>
	<media:keywords><![CDATA[naproxen,pegfilgrastim]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
